Arca
Skip to content
Tools
Tools

Label Changes: Tecentriq (atezolizumab)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Tecentriq label DailyMed has published, from Genentech, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 37
  • Sections changed, version 45 to 46: 9

What changed from version 45 to version 46

May 28, 2026 to Oct 16, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged · 47 words added
  2. Dosage and administrationChanged · 279 words added, 159 removed
  3. Warnings and precautionsChanged · 1 word added, 1 removed
  4. Adverse reactionsChanged · 485 words added, 1 removed
  5. Use in specific populationsChanged · 274 words added
  6. Clinical pharmacologyChanged · 88 words added, 73 removed
  7. Clinical studiesChanged · 504 words added, 22 removed
  8. Patient counseling informationChanged · punctuation or symbols only
  9. Medication guideChanged · 122 words added, 5 removed

Indications and usage

Changed47 words added
17 unchanged lines
TECENTRIQ, as a single agent, is indicated as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test [see Dosage and Administration (2.1)].
1.7 Mismatch Repair–Deficient Colon Cancer
TECENTRIQ, in combination with a fluoropyrimidine and oxaliplatin, is indicated for the adjuvant treatment of adult and pediatric patients 2 years of age and older with Stage III, mismatch repair deficient (dMMR) colon cancer [see Dosage and Administration (2.1)].

Dosage and administration

Changed279 words added, 159 removed
2 DOSAGE AND ADMINISTRATION
2.1 Patient Selection for Treatment of Non-Small Cell Lung Cancer, Melanoma, and Muscle Invasive Bladder Cancer, and Colon Cancer
Select patients with:
Select patients with Stage II to IIIA non-small cell lung cancerNSCLC for treatment with TECENTRIQ as a single agent based on PD-L1 expression on tumor cells [see Clinical Studies (14.1)].
Select patients with firstFirst-line metastatic non-small cell lung cancerNSCLC for treatment with TECENTRIQ as a single agent based on the PD-L1 expression on tumor cells or on tumor-infiltrating immune cells [see Clinical Studies (14.1)].
Unresectable or metastatic melanoma for treatment with TECENTRIQ in combination with cobimetinib and vemurafenib after confirming the presence of a BRAF V600 mutation [see Clinical Studies (14.4)].
Muscle invasive bladder cancer for treatment with TECENTRIQ as a single agent based on detection of ctDNA MRD in plasma via serial testing between six weeks and one year after cystectomy [see Clinical Studies (14.6)].
Stage III colon cancer for treatment with TECENTRIQ in combination with chemotherapy based on dMMR tumor status in tumor specimens [see Clinical Studies (14.7)].
Information on FDA-authorized tests for the determination of PD-L1 expression in metastatic non-small cell lung cancer are available at: http://www.fda.gov/CompanionDiagnostics.
Information regarding FDA-authorized tests for determining PD-L1 expression in metastatic NSCLC, detecting BRAF V600 mutations in melanoma, and determining ctDNA MRD status in MIBC are available at: http://www.fda.gov/CompanionDiagnostics.
Select patients with unresectable or metastatic melanoma for treatment with TECENTRIQ in combination with cobimetinib and vemurafenib after confirming the presence of a BRAF V600 mutation [see Clinical Studies (14.4)]. Information on FDA-authorized tests for the detection of BRAF V600 mutations in melanoma is available at: http://www.fda.gov/CompanionDiagnostics.
Select patients with muscle invasive bladder cancer for treatment with TECENTRIQ as a single agent based on detection of ctDNA MRD in plasma via serial testing between six weeks and one year after cystectomy [see Clinical Studies (14.6)].
Information on FDA-authorized tests for the determination of ctDNA MRD status in MIBC is available at: http://www.fda.gov/CompanionDiagnostics.
An FDA-authorized test for detection of dMMR tumor status in patients with colon cancer is not currently available.
2.2 Recommended Dosage
5 unchanged lines
ASPS (adult) | 840 mg every 2 weeks or 1200 mg every 3 weeks or 1680 mg every 4 weeks | Until disease progression or unacceptable toxicity
ASPS (pediatric, 2 years of age and older) | 15 mg/kg (up to a maximum of 1200 mg) every 3 weeks
MIBC | 840 mg every 2 weeks or 1200 mg every 3 weeks or 1680 mg every 4 weeks | Up to one year, unless there is disease recurrence or unacceptable toxicity
6 unchanged lines
Melanoma | 840 mg every 2 weeks or 1200 mg every 3 weeks or 1680 mg every 4 weeks Administer TECENTRIQ with cobimetinib 60 mg orally once daily (21 days on and 7 days off) and vemurafenib 720 mg orally twice daily. Prior to initiating TECENTRIQ, patients should receive a 28-day treatment cycle of cobimetinib 60 mg orally once daily (21 days on and 7 days off) and vemurafenib 960 mg orally twice daily from Days 1-21 and vemurafenib 720 mg orally twice daily from Days 22-28.
Colon Cancer (adults) | 840 mg every 2 weeks or 1200 mg every 3 weeks or 1680 mg every 4 weeks Administer TECENTRIQ prior to chemotherapy when given on the same day. | In combination with chemotherapy for 6 months , followed by TECENTRIQ as a single agent for 6 months or until disease recurrence or unacceptable toxicity.
Colon Cancer (pediatric patients 2 years of age and older) | 10 mg/kg (up to a maximum of 840 mg) every 2 weeks, 15 mg/kg (up to a maximum of 1200 mg) every 3 weeks, or Administer TECENTRIQ prior to chemotherapy when given on the same day. | In combination with chemotherapy for 6 months, followed by TECENTRIQ as a single agent for 6 months or until disease recurrence or unacceptable toxicity
2.3 Dosage Modifications for Adverse Reactions
46 unchanged lines

Warnings and precautions

Changed1 word added, 1 removed
92 unchanged lines
Hematologic/Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection.
Other: Myocarditis-Myositis-Myasthenia Gravis (or Myasthenia-Like) Overlap Syndrome, reported as the co-occurenceoccurrence of either two or all three adverse reactions.
5.2 Infusion-Related Reactions
8 unchanged lines

Adverse reactions

Changed485 words added, 1 removed
390 unchanged lines
IMspire150
The safety of TECENTRIQ, administered with cobimetinib and vemurafenib was evaluated in IMspire150, a double-blind, randomized (1:1), placebo-controlled study conducted in patients with previously untreated BRAF V600 mutation-positive metastatic or unresectable melanoma [see Clinical Studies (14.4)]. Patients received TECENTRIQ with cobimetinib and vemurafenib (N=230) or placebo with cobimetinib and vemurafenib (nN=281).
Among the 230 patients who received TECENTRIQ administered with cobimetinib and vemurafenib, the median duration of exposure to TECENTRIQ was 9.2 months (range: 0-30 months) to cobimetinib was 10.0 months (range: 1-31 months) and to vemurafenib was 9.8 months (range: 1-31 months).
170 unchanged lines
Increased alkaline phosphatase | 23 | 1.2 | 15 | 0
Adjuvant Treatment of Stage III dMMR Colon Cancer
ATOMIC (ML39057) Study
The safety of TECENTRIQ was evaluated in ATOMIC, a multicenter, randomized, open-label, active-controlled trial in 345 adults and one pediatric patient with Stage III dMMR colon cancer [see Clinical Studies (14.7)]. Adults received TECENTRIQ 840 mg every 2 weeks. The pediatric patient received 10 mg/kg Q2W until the maximum dose of 840 mg Q2W. All patients received TECENTRIQ in combination with mFOLFOX6 for 6 months (12 cycles), followed by TECENTRIQ monotherapy for 6 months (13 cycles), or mFOLFOX6 alone for 6 months (12 cycles), until disease recurrence, unacceptable toxicity, or patient or physician decision to discontinue. The total duration of treatment was up to one year. Among patients receiving TECENTRIQ in combination with mFOLFOX6, the median duration of exposure to TECENTRIQ was 10.9 months.
Serious adverse reactions occurred in 52% of patients receiving TECENTRIQ in combination with mFOLFOX6. The most frequent serious adverse reactions (≥3%) were diarrhea (8%), nausea (6%), abdominal pain (4.9%), peripheral sensory neuropathy (4.6%) and pyrexia (3.8%).
Adverse reactions leading to permanent discontinuation of TECENTRIQ occurred in 17% of patients. The most frequent adverse reactions leading to permanent discontinuation of TECENTRIQ were peripheral sensory neuropathy (5%), neuropathy peripheral (3%) and paresthesia (2%).
Table 26 and 27 summarize adverse reactions and laboratory abnormalities in ATOMIC.
Table 26: Adverse Reactions Occurring in ≥20% (with a difference between arms of at least 5% incidence) Patients with Colon Cancer Receiving TECENTRIQ in ATOMIC
Adverse Reaction | TECENTRIQ in combination with mFOLFOX6 (n=346) | mFOLFOX6 (n=334)
All Grades (%) | Grade 3–4 (%) | All Grades (%) | Grade 3–4 (%)
Gastrointestinal Disorders
Nausea | 75 | 4.6 | 69 | 1.2
Diarrhea | 73 | 14 | 61 | 9
Abdominal pain | 47 | 4.6 | 30 | 2.1
Constipation | 43 | 0 | 34 | 0
Stomatitis | 34 | 2.6 | 33 | 1.2
Vomiting | 26 | 2.6 | 21 | 1.2
Nervous System Disorders
Peripheral sensory neuropathy | 62 | 12 | 55 | 11
Neuropathy peripheral | 38 | 6 | 30 | 5
Metabolism and Nutrition Disorders
Decreased appetite | 48 | 2.0 | 38 | 0
Respiratory, Thoracic and Mediastinal Disorders
Cough | 42 | 0.3 | 23 | 0
Dyspnea | 35 | 2.0 | 24 | 1.2
General Disorders and Administration Site Conditions
Pyrexia | 21 | 0 | 7 | 0.3
Table 27: Laboratory Abnormalities Worsening from Baseline Occurring in ≥20% (with a difference between arms of at least 5% incidence or 2% of Grade 3–4 abnormalities) of Patients with Colon Cancer Receiving TECENTRIQ in ATOMIC
Laboratory Abnormality | TECENTRIQ in combination with mFOLFOX6 | mFOLFOX6
All Grades (%) | Grade 3–4 (%) | All Grades (%) | Grade 3–4 (%)
Hematology
Hemoglobin decreased | 68 | 10 | 60 | 7
Total leukocyte count decreased | 61 | 2 | 53 | 2
Total neutrophils decreased | 53 | 10 | 49 | 6
Lymphocytes decreased | 43 | 5 | 32 | 2
Chemistry
Alkaline phosphatase increased | 51 | 2 | 47 | 0
Hypokalemia | 34 | 7 | 31 | 4
Calcium decreased | 33 | 2 | 19 | 1
Sodium decreased | 25 | 2 | 16 | 2
Creatinine increased | 22 | 2 | 14 | < 1
6.2 Postmarketing Experience
3 unchanged lines

Use in specific populations

Changed274 words added
24 unchanged lines
The safety and effectiveness of TECENTRIQ for ASPS have not been established in pediatric patients younger than 2 years of age.
Colon Cancer
The safety and effectiveness of TECENTRIQ have been established in pediatric patients 2 years of age and older for the adjuvant treatment of Stage III dMMR colon cancer. Use of TECENTRIQ for this indication is supported by evidence from an adequate and well-controlled study in adults and one adolescent patient (≥12 years of age) with Stage III dMMR colon cancer with additional pharmacokinetic and safety data in pediatric patients 2 years to <17 years. These data suggest that atezolizumab exposure in pediatric patients aged 2 years and older is comparable with that of adults and is expected to result in similar safety and efficacy to that of adults [see Adverse Reactions (6.1), Pharmacokinetics (12.3), Clinical Studies (14.7)]. The course of Stage III dMMR colon cancer is sufficiently similar between pediatric patients 2 to 11 years old and that of adults and adolescent patients to allow extrapolation of efficacy and safety to pediatric patients 2 years and older.
The safety and effectiveness of TECENTRIQ have not been established in pediatric patients younger than 2 years of age with colon cancer.
Solid Tumors and Lymphomas
11 unchanged lines
Of the 242 patients with ES-SCLC treated with TECENTRIQ in combination with lurbinectedin in IMforte, 124 (51%) patients were 65 years of age and older, while 29 (12%) patients were 75 years of age and older. No overall differences in effectiveness were observed between older and younger patients. There was a higher incidence of Grade 3 or 4 adverse reactions (45% vs 31%) and treatment discontinuation (11% vs 0.8%) in patients ≥ 65 years of age compared to younger patients, respectively.
TECENTRIQ in Combination with Chemotherapy
Of the 346 patients with colon cancer treated with TECENTRIQ in combination with mFOLFOX6, 170 (49%) patients were 65 years of age and older, and 69 (20%) patients were 75 years of age and older. No overall differences in effectiveness were observed between patients aged 65 years or older and younger patients. There was a higher incidence of Grade 3 or 4 adverse reactions (87% vs 79%) and treatment discontinuation (20% vs 15%) in patients ≥65 years of age compared to younger patients, respectively.

Clinical pharmacology

Changed88 words added, 73 removed
15 unchanged lines
Pediatric Patients
Atezolizumab serum concentrations with weight-based dosing at 15 mg/kg up to a maximum of 1200 mg every 3 weeks, in pediatric patients (2 years to <17 years) with relapsed or progressive solid tumors and lymphomas, are comparable to those of adult patients receiving 1200 mg every 3 weeks; while the exposure tended to be lower in pediatric patients less than 12 years old, this is not considered to be clinically relevant.
Atezolizumab serum concentrations in pediatric patients (ages 2 to < 17 years) are predicted to be within the range of those observed in adults receiving the corresponding recommended doses. This applies to weight-based dosing at 10 mg/kg (up to a maximum of 840 mg) every 2 weeks and 15 mg/kg (up to a maximum of 1,200 mg) every 3 weeks. While the exposure tended to be lower in pediatric patients less than 12 years old, this is not considered to be clinically relevant.
12.6 Immunogenicity
1 unchanged line
During the first year of treatment with TECENTRIQ across 9 clinical studies, 13% to 36% of patients developed ADA to atezolizumab. Median atezolizumab clearance in patients who tested positive for ADA was 20% (minimum 10%, maximum 49%) higher as compared to atezolizumab clearance in patients who tested negative for ADA; this change in clearance is not expected to be clinically significant.
In OAK and IMbrave150, exploratory analyses showed that the subset of patients who were ADA-positive appeared to have less efficacy (effect on overall survival) as compared to patients who tested negative for ADA [see Clinical Studies (14.1, 14.3)]. In study IMpower150 and IMforte, the impact of ADA on efficacy did not appear to be clinically significant [see Clinical Studies (14.1, 14.2)]. In the remaining studies, there is insufficient information to characterize the effect of ADA on efficacy.
The presence of ADA did not have a clinically significant effect on the incidence or severity of adverse reactions.
1 unchanged line

Clinical studies

Changed504 words added, 22 removed
8 unchanged lines
At the time of the interim DFS analysis, the study demonstrated a statistically significant improvement in DFS in the PD-L1 ≥ 1% TC, Stage II – IIIA patient population.
Efficacy results are presented in Table 2628 and Figure 1.
Table 2628: Efficacy Results from IMpower010 in Patients with Stage II - IIIA NSCLC with PD-L1 expression ≥ 1% TC
| Arm A: TECENTRIQ N = 248 | Arm B: Best Supportive Care N = 228
19 unchanged lines
Among the 205 chemotherapy-naïve patients with stage IV NSCLC with high PD-L1 expression (TC ≥ 50% or IC ≥ 10%) excluding those with EGFR or ALK genomic tumor aberrations, the median age was 65.0 years (range: 33 to 87), and 70% of patients were male. The majority of patients were White (82%) and Asian (17%). Baseline ECOG performance status was 0 (36%) or 1 (64%); 88% were current or previous smokers; and 76% of patients had non-squamous disease while 24% of patients had squamous disease.
The trial demonstrated a statistically significant improvement in OS for patients with high PD-L1 expression (TC ≥50% or IC ≥10%) at the time of the OS interim analysis. There was no statistically significant difference in OS for the other two PD-L1 subgroups (TC ≥5% or IC ≥5%; and TC ≥1% or IC ≥1%) at the interim or final analyses. Efficacy results for patients with NSCLC with high PD-L1 expression are presented in Table 2729 and Figure 2.
Table 2729: Efficacy Results from IMpower110 in Patients with NSCLC with High PD-L1 Expression (TC ≥ 50% or IC ≥ 10%) and without EGFR or ALK Genomic Tumor Aberrations
| Arm A: TECENTRIQ N = 107 | Arm B: Platinum-Based Chemotherapy N = 98
21 unchanged lines
A total of 1202 patients were enrolled across the three arms of whom 1045 were in the ITT-WT subpopulation and 447 were in the tGE-WT subpopulation. The demographic information is limited to the 800 patients enrolled in Arms B and C where efficacy has been demonstrated. The median age was 63 years (range: 31 to 90), and 60% of patients were male. The majority of patients were White (82%), 13% of patients were Asian, 10% were Hispanic, and 2% of patients were Black. Clinical sites in Asia (enrolling 13% of the study population) received paclitaxel at a dose of 175 mg/m2 while the remaining 87% received paclitaxel at a dose of 200 mg/m2. Approximately 14% of patients had liver metastases at baseline, and most patients were current or previous smokers (80%). Baseline ECOG performance status was 0 (43%) or 1 (57%). PD-L1 was TC3 and any IC in 12%, TC0/1/2 and IC2/3 in 13%, and TC0/1/2 and IC0/1 in 75%. The demographics for the 696 patients in the ITT-WT subpopulation were similar to the ITT population except for the absence of patients with EGFR- or ALK- positive NSCLC.
The trial demonstrated a statistically significant improvement in PFS between Arms B and C in both the tGE-WT and ITT-WT subpopulations, but did not demonstrate a significant difference for either subpopulation between Arms A and C based on the final PFS analyses. In the interim analysis of OS, a statistically significant improvement was observed for Arm B compared to Arm C, but not for Arm A compared to Arm C. Efficacy results for the ITT-WT subpopulation are presented in Table 2830 and Figure 3.
Table 2830: Efficacy Results in ITT-WT Population in IMpower150
| Arm C: Bevacizumab, Paclitaxel and Carboplatin | Arm B: TECENTRIQ with Bevacizumab, Paclitaxel, and Carboplatin | Arm A: TECENTRIQ with Paclitaxel, and Carboplatin
29 unchanged lines
A total of 724 patients were enrolled; of these, 681 (94%) were in the ITT-WT population. The median age was 64 years (range: 18 to 86) and 59% were male. The majority of patients were white (90%), 2% of patients were Asian, 5% were Hispanic, and 4% were Black. Baseline ECOG performance status was 0 (41%) or 1 (58%). Most patients were current or previous smokers (90%). PD-L1 tumor expression was TC0/1/2 and IC0/1 in 73%; TC3 and any IC in 14%; and TC0/1/2 and IC2/3 in 13%.
Efficacy results for the ITT-WT population are presented in Table 2931 and Figure 4.
Table 2931: Efficacy Results from IMpower130
| TECENTRIQ with Paclitaxel Protein-Bound and Carboplatin | Paclitaxel Protein-Bound and Carboplatin
26 unchanged lines
Among the first 850 randomized patients, the median age was 64 years (33 to 85 years) and 47% were ≥ 65 years old; 61% were male; 70% were White and 21% were Asian; 15% were current smokers and 67% were former smokers; and 37% had baseline ECOG performance status (PS) of 0 and 63% had a baseline ECOG PS of 1. Nearly all (94%) had metastatic disease, 74% had non-squamous histology, 75% had received only one prior platinum-based chemotherapy regimen, and 55% of patients had PD-L1-expressing tumors.
Efficacy results are presented in Table 3032 and Figure 5.
Table 3032: Efficacy Results in OAK
| TECENTRIQ | Docetaxel
42 unchanged lines
A total of 403 patients were randomized, including 201 to the TECENTRIQ arm and 202 to the chemotherapy alone arm. The median age was 64 years (range 26 to 90) and 65% were male. The majority of patients were White (80%); 17% were Asian, 4% were Hispanic and 1% were Black. Baseline ECOG performance status was 0 (35%) or 1 (65%); 9% of patients had a history of brain metastases, and 97% were current or previous smokers.
Efficacy results are presented in Table 3133 and Figure 6.
Table 3133: Efficacy Results from IMpower133
| TECENTRIQ with Carboplatin and Etoposide | Placebo with Carboplatin and Etoposide
29 unchanged lines
A total of 483 patients were randomized, including 242 to the TECENTRIQ with lurbinectedin arm and 241 to the TECENTRIQ arm. The median age was 66 years (range 35 to 85 years); 63% male; 82% White; 13% Asian; 0.8% were Black or African American; 7% were of Hispanic or Latino ethnicity and 98% were current or previous smokers. Baseline ECOG performance status was 0 (43%) or 1 (57%).
Efficacy results are presented in Table 3234 and Figures 7 and 8.
Table 3234: Efficacy Results from IMforte
| TECENTRIQ with Lurbinectedin N=242 | TECENTRIQ N=241
20 unchanged lines
The major efficacy outcome measures were overall survival (OS) and independent review facility (IRF)-assessed progression free survival (PFS) per RECIST v1.1. Additional efficacy outcome measures were IRF-assessed overall response rate (ORR) per RECIST and mRECIST.
Efficacy results are presented in Table 3335 and Figure 9.
Table 3335: Efficacy Results from IMbrave150
| TECENTRIQ in combination with Bevacizumab (N= 336) | Sorafenib (N=165)
37 unchanged lines
The median age of the study population was 54 years (range: 22-88), 58% of patients were male, 95% were White, a baseline ECOG performance status of 0 (77%) or 1 (23%), 33% had elevated LDH, 94% had metastatic disease, 60% were Stage IV (M1C), 56% had less than three metastatic sites at baseline, 3% had prior treatment for brain metastases, 30% had liver metastases at baseline, and 14% had received prior adjuvant systemic therapy. Based on central testing, 74% were identified as having a V600E mutation, 11% as having V600K mutation, and 1% as having V600D or V600R mutations.
Efficacy results are summarized in Table 3436 and Figure 10. Patients had a median survival follow up time of 18.9 months.
Table 3436: Efficacy Results from IMspire150
| TECENTRIQ + Cobimetinib + Vemurafenib N=256 | Placebo + Cobimetinib + Vemurafenib N=258
21 unchanged lines
A total of 49 patients were enrolled. The median age of patients was 31 years (range: 12-70); 2% of adult patients (n=47) were ≥65 years of age and the pediatric patients (n=2) were ≥12 years of age; 51% of patients were female, 55% White, 29% Black or African American, 10% Asian; 53% had an ECOG performance status of 0 and 45% had an ECOG performance status of 1. All patients had prior surgery for ASPS and 55% received at least one prior line of treatment for ASPS; 55% received radiotherapy and 53% received chemotherapy. Of the patients who reported staging at initial diagnosis, all were Stage IV.
Efficacy results of this study are summarized in Table 3537.
Table 3537: Efficacy Results from Study ML39345
Endpoint | All Patients (N=49)
23 unchanged lines
The major efficacy outcome measure was investigator-assessed disease-free survival (DFS). Overall Survival (OS) was an additional efficacy measure.
The study demonstrated statistically significant improvements in DFS and OS for patients randomized to the TECENTRIQ arm compared with placebo. Efficacy results are presented in Table 3638 and Figures 11 and 12.
Table 3638: Efficacy Results from IMvigor011
| TECENTRIQ N=167 | Placebo N=83
15 unchanged lines
In a pre-specified exploratory analysis based on time from cystectomy to first ctDNA MRD positive sample, the unstratified hazard ratio (HR) for investigator-assessed DFS in the subgroup of patients who had ≤20 weeks to first ctDNA MRD positive sample (n=176), was 0.52 (95% CI: 0.37, 0.74), with median DFS of 8.3 months (95% CI: 6.2, 12.7) in the TECENTRIQ arm and 4.1 months (95% CI: 2.3, 6.2) in the placebo arm. The unstratified HR for OS was 0.63 (95% CI: 0.39, 1.00), with median OS of 32.8 months (95% CI: 24.4, not reached) in the TECENTRIQ arm and 18.2 months (95% CI: 13.1, not reached) in the placebo arm. In the subgroup of patients who had >20 weeks to first ctDNA MRD positive sample (n=74), the unstratified HR for investigator-assessed DFS was 1.04 (95% CI: 0.54, 1.97), with median DFS of 10.5 months (95% CI: 6.9, 20.9) in the TECENTRIQ arm and 10.5 months (95% CI: 6.5, 20.5) in the placebo arm. The unstratified HR for OS was 0.77 (95% CI: 0.30, 1.96); median OS was not reached in either arm (95% CI: 21.1 months, not reached in the TECENTRIQ arm and 18.4 months, not reached in the placebo arm).
14.7 dMMR Colon Cancer
The efficacy of TECENTRIQ in combination with mFOLFOX6 (oxaliplatin, leucovorin, and fluorouracil) was evaluated in ATOMIC/ML39057 (NCT02912559), a multicenter, randomized, open-label, active-controlled study in 711 adults and one pediatric patient with Stage III dMMR colon cancer after a complete (R0) resection of the primary tumor with no evidence of residual lymph node involvement or metastatic disease. Patients were excluded if they had a rectal tumor (tumor must be in the colon); prior chemotherapy, radiation, or drug therapies (with the exception of one cycle of mFOLFOX6); a history of active autoimmune disease; pulmonary disease with hypoxia; grade 2 or higher peripheral motor or sensory neuropathy .Patients were randomized (1:1) to receive one of the following:
TECENTRIQ 840 mg IV once every 2 weeks (the pediatric patient received 10 mg/kg Q2W, until reaching 840 mg) in combination with mFOLFOX6 (oxaliplatin, leucovorin, and fluorouracil) for 6 months (12 cycles), followed by TECENTRIQ IV monotherapy for 6 months (13 cycles), or
mFOLFOX6 every 2 weeks for 6 months (12 cycles).
mFOLFOX6 consisted of oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, and fluorouracil 400 mg/m2 given as a bolus followed by fluorouracil 2400 mg/m2 given as a continuous infusion over 46 hours. Randomization was stratified by nodal status (N1/N1C vs. N2), tumor stage (Tx, T1-T3 vs. T4), and primary tumor location (proximal vs. distal). Study treatment was administered for the planned duration unless disease recurrence or unacceptable toxicity. Tumor assessments per RECIST v1.1 were conducted every 6 months for the first 2 years and then annually for 3 years.
The median age was 64 years (range: 13 to 91 years); 49% were ≥65 years of age, 55% female, 45% male; 85% of patients were White, 7% were Black or African American and 3.1% were Asian; 7% were Hispanic or Latino, 90% not Hispanic or Latino, and 3.3% not reported or unknown.
Baseline ECOG performance status was 0 in 65%, 1 in 33%, and 2 in 1.5%. Overall, 70% of patients had tumor stage Tx, T1-T3 and 30% had T4 tumors. Sixty-four percent of patients had N1/N1C nodal status (1-3 positive nodes) and 36% had N2 nodal status (≥ 4 positive nodes). Tumor location was right-sided in 84% of patients and left-sided in 16% of patients. The major efficacy outcome measure was disease-free survival (DFS) as assessed by the investigator.
Efficacy results are summarized in Table 39 and Figure 13.
Table 39: Efficacy Results from ATOMIC
Endpoint | TECENTRIQ + mFOLFOX6 (n=355) | mFOLFOX6 (n=357)
CI: confidence interval; NR = Not Reached
Disease-Free Survival (DFS) | |
Number of events (%) | 46 (13%) | 81 (23%)
Median DFS (months) (95% CI) | NR | NR
Hazard Ratio (95% CI) | 0.50 (0.35, 0.73)
p-value | 0.0001
Figure 13: Kaplan-Meier Plot of Disease-Free Survival in ATOMIC

Patient counseling information

Changedpunctuation or symbols only
7 unchanged lines
Endocrinopathies: Advise patients to contact their healthcare provider immediately for signs or symptoms of hypophysitis, hyperthyroidism, hypothyroidism, adrenal insufficiency, or type 1 diabetes mellitus, including diabetic ketoacidosis [see Warnings and Precautions (5.1)].
Nephritis: Advise patients to contact their healthcare provider immediately for pelvic pain, frequent urination, or unusual swelling. [see Warnings and Precautions (5.1)].
Dermatologic Adverse Reactions: Advise patients to contact their healthcare provider immediately for generalized rash, skin eruption, or painful skin and mucous membrane lesions [see Warnings and Precautions (5.1)].
10 unchanged lines

Medication guide

Changed122 words added, 5 removed
MEDICATION GUIDE TECENTRIQ® (te-SEN-trik) (atezolizumab) Injectioninjection, for intravenous use
This Medication Guide has been approved by the U.S. Food and Drug Administration. | Revised: 0510/2026
What is the most important information I should know about TECENTRIQ?
21 unchanged lines
TECENTRIQ is a prescription medicine used to treat:
adults with a type of lung cancer called non-small cell lung cancer (NSCLC). TECENTRIQ may be used alone as a treatment for your lung cancer: to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery and you have received platinum-based chemotherapy, and you have stage 2 to stage 3A NSCLC (talk to your healthcare provider about what these stages mean), and your cancer tests positive for "PD-L1". TECENTRIQ may be used alone as your first treatment when your lung cancer: has spread or grown, and your cancer tests positive for "high PD-L1", and your tumor does not have an abnormal "EGFR" or "ALK" gene. TECENTRIQ may be used with the medicines bevacizumab, paclitaxel, and carboplatin as your first treatment when your lung cancer: has spread or grown, and is a type called "non-squamous NSCLC", and your tumor does not have an abnormal "EGFR" or "ALK" gene. TECENTRIQ may be used with the medicines paclitaxel protein-bound and carboplatin as your first treatment when your lung cancer: has spread or grown, and is a type called "non-squamous NSCLC", and your tumor does not have an abnormal "EGFR" or "ALK" gene. TECENTRIQ may also be used alone when your lung cancer: has spread or grown, and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. if your tumor has an abnormal "EGFR" or "ALK" gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working. adults with a type of lung cancer called extensive-stage small cell lung cancer (SCLC), which is SCLC that has spread or grown. TECENTRIQ may be used with the chemotherapy medicines carboplatin and etoposide as your first treatment. TECENTRIQ may be used with the medicine lurbinectedin as maintenance treatment when your lung cancer: has not progressed after first treatment with TECENTRIQ or atezolizumab and hyaluronidase-tqjs and the chemotherapy medicines carboplatin and etoposide. adults with a type of liver cancer called hepatocellular carcinoma (HCC). TECENTRIQ may be used with the medicine bevacizumab when your liver cancer: has spread or cannot be removed by surgery, and you have not received other medicines by mouth or injection through your vein (IV) to treat your cancer. adults with a type of skin cancer called melanoma. TECENTRIQ may be used with the medicines cobimetinib and vemurafenib when your melanoma: has spread to other parts of the body or cannot be removed by surgery, and has a certain type of abnormal "BRAF" gene. Your healthcare provider will perform a test to make sure this TECENTRIQ combination is right for you. adults and children 2 years of age and older with a type of soft tissue tumor (cancer) called alveolar soft part sarcoma (ASPS). TECENTRIQ may be used alone when your sarcoma: has spread to other parts of the body or cannot be removed by surgery. adults with a type of bladder cancer called muscle invasive bladder cancer (MIBC) that has spread into the muscle layer of the bladder but not to other parts of the body. TECENTRIQ may be used alone as a treatment for your bladder cancer: to help prevent your bladder cancer from coming back after your bladder has been removed by surgery, and small pieces of DNA from the tumor (called circulating tumor DNA [ctDNA]) were found in your blood, showing that cancer cells remain in the body (molecular residual disease). Your healthcare provider will perform a test to make sure that TECENTRIQ is right for you. Adults and children 2 years of age and older with a type of colon cancer. TECENTRIQ may be used with a fluoropyrimidine and oxaliplatin medicine: to help prevent your colon cancer from coming back after your tumor(s) have been removed by surgery, and you have stage 3 colon cancer, and your tumor has been shown by a laboratory test to be mismatch repair deficient (dMMR)
It is not known if TECENTRIQ is safe and effective when used: in children: younger than 2 years of age for the treatment of ASPS. inor childrencolon cancer. for the treatment of NSCLC, SCLC, HCC, melanoma, or MIBC.
Before receiving TECENTRIQ, tell your healthcare provider about all of your medical conditions, including if you:
14 unchanged lines
| skin rash joint, muscle, or bone pain feeling tired or weak liver injury | fever nausea itching swelling of legs or arms | mouth swelling (sometimes with sores) low thyroid hormone levels sunburn or sun sensitivity
The most common side effects of TECENTRIQ when used in colon cancer with a fluoropyrimidine and oxaliplatin include:
| nausea diarrhea numbness, tingling, or pain in the hands or feet decreased appetite | stomach-area (abdominal) pain constipation cough shortness of breath | mouth swelling (sometimes with sores) vomiting fever
TECENTRIQ may cause fertility problems in females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.
These are not all of the possible side effects of TECENTRIQ.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
8 unchanged lines

Unchanged: Dosage forms and strengths, Contraindications, Description, Nonclinical toxicology, How supplied, Untitled section, PRINCIPAL DISPLAY PANEL - 20 mL Vial Carton, PRINCIPAL DISPLAY PANEL - 14 mL Vial Carton.

Every version

37 versions of set 6fa682c9-a312-4932-9831-f286908660ee, newest first.
VersionPublished on DailyMedCompareSPL file
46Oct 16, 2026Shown belowDownload .zip
45May 28, 2026With version 44Download .zip
44Apr 8, 2026With version 43Download .zip
43Nov 27, 2025With version 42Download .zip
42Nov 17, 2025With version 39Download .zip
39Aug 28, 2025With version 37Download .zip
37Nov 22, 2024With version 36Download .zip
36Jul 12, 2024With version 35Download .zip
35Jun 21, 2024With version 34Download .zip
34May 23, 2023With version 33Download .zip
33Dec 20, 2022With version 32Download .zip
32Feb 2, 2022With version 31Download .zip
31Nov 1, 2021With version 30Download .zip
30Oct 21, 2021With version 27Download .zip
27Apr 22, 2021With version 25Download .zip
25Feb 25, 2021With version 24Download .zip
24Dec 29, 2020With version 21Download .zip
21Nov 23, 2020With version 20Download .zip
20Oct 7, 2020With version 19Download .zip
19Aug 12, 2020With version 18Download .zip
18Jun 5, 2020With version 17Download .zip
17Jun 1, 2020With version 16Download .zip
16Dec 18, 2019With version 15Download .zip
15Nov 22, 2019With version 14Download .zip
14May 15, 2019With version 13Download .zip
13Apr 5, 2019With version 12Download .zip
12Apr 1, 2019With version 10Download .zip
10Mar 15, 2019With version 9Download .zip
9Jan 29, 2019With version 8Download .zip
8Dec 19, 2018With version 7Download .zip
7Jul 17, 2018With version 6Download .zip
6May 11, 2018With version 5Download .zip
5Mar 23, 2018With version 4Download .zip
4Nov 9, 2017With version 3Download .zip
3Apr 28, 2017With version 2Download .zip
2Oct 27, 2016With version 1Download .zip
1May 24, 2016First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.